Selexis CHO Cells in Suspension-1


Selexis enables biopharmaceutical companies to produce virtually any recombinant therapeutic protein, because we have the ability to understand and modify our cells to address productivity and expression challenges.

Selexis - Success Story | Selexis SA

APRIL 13, 2019

Since 1989, the W.A. De Vigier has been helping Swiss startups. Learn how De Vigier helped Selexis in our early days. And for more information on the foundation, please visit


Protein Expression Issues: SURE CHO-MPLUS Libraries

SEPTEMBER 29, 2017

Leveraging our knowledge of the data from the Selexis SURE CHO-M genome and transcriptome, we identified areas within the CHO-M secretory pathways that could be modified to address particular issues such as stalled translocation, improper folding, incomplete post-translational modifications, chromosomal instability or insufficient cellular respiration to handle the increased protein load.